Cancer Victim Sues Monsanto, Says It Misrepresented Safety Of Roundup, Glyphosate

SAN FRANCISCO - A California man on June 21 sued Monsanto Co. in California federal court, contending that he has developed non-Hodgkin lymphoma (NHL) as a result of exposure to glyphosate, the active ingredient in the herbicide Roundup, which he alleges Monsanto has misrepresented as a safe product (Saul Cohen v. Monsanto Company, No. 19-3632, N.D. Calif.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news

Related Links:

AbstractA balanced robertsonian translocation (rob) results from fusion of 2 acrocentric chromosomes. Carriers are phenotypically normal and are often diagnosed because of recurrent miscarriages, infertility, or aneuploid offspring. Mortality and site-specific cancer risks in carriers have not been prospectively investigated. We followed 1,987 carriers diagnosed in Great Britain for deaths and cancer risk, over an average of 24.1 years. Standardized mortality and incidence ratios were calculated comparing the number of observed events against population rates. Overall mortality was higher for carriers diagnosed before age ...
Source: American Journal of Epidemiology - Category: Epidemiology Source Type: research
Conclusions: In this simulation, the incremental costs of FN-related hospitalization due to PEG-OBI failure in cycle 1 compared to assured prophylaxis with reference pegfilgrastim, reference filgrastim, and biosimilar filgrastim-sndz varied depending upon the PEG-OBI failure rate and the alternative G-CSF prophylaxis option. Biosimilar filgrastim-sndz offers the greatest cost-efficiency. PMID: 31433700 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
ConclusionsOur results suggest that registry-based collection of PGHD is acceptable to most cancer survivors and could facilitate registry-based efforts to collect PGHD/PROs. Central cancer registry-based collection of PGHD/PROs, especially on long-term effects, could enhance registry support of cancer control efforts including research and population health management.
Source: Quality of Life Research - Category: Health Management Source Type: research
Targeted therapy is revolutionizing the treatment of cancers, but resistance evolves against these therapies and derogates their success. The phosphatidylinositol 3-kinase delta (PI3K-) inhibitor idelalisib has been approved for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, but the mechanisms conferring resistance in a subset of patients are unknown. Here, we modeled resistance to PI3K- inhibitor in vivo using a serial tumor transfer and treatment scheme in mice. Whole-exome sequencing did not identify any recurrent mutation explaining resistance to PI3K- inhibitor. In the murine model, resistan...
Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia Source Type: research
The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study. Material and methods: Analyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer di...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Magdalena Bujalski, 22, of Winnipeg, Canada, was told her cough was likely just bronchitis, until an X-ray revealed an unusual mass on her right lung. She was diagnosed with Non-Hodgkin Lymphoma.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Abstract BACKGROUND: A cohort of male lead-exposed workers with past blood lead levels, previously followed for mortality over 12 years, has now been followed for an additional 10 years. This has doubled the number of deaths and allowed for examination of mortality outcomes across a wide range of blood lead levels. OBJECTIVE: Evaluate association between lead exposure and 16 causes of death. METHODS: The cohort included male workers from 11 U.S. states enrolled in a U.S. lead surveillance program. Maximum blood lead level for each worker was abstracted from surveillance records. Mortality was assessed us...
Source: Environmental Research - Category: Environmental Health Authors: Tags: Environ Res Source Type: research
The objectives of this study were to analyze the clinical features of patients with bone involved lymphoma and identify the prognostic factors and to explore the optimized treatment strategy for bone involved lymphoma. A total of 1948 patients with lymphoma in our cancer center from September 2006 to October 2017 were retrospectively evaluated. Among these, 109 patients with skeletal involvement in lymphoma were enrolled. According to the pathologic subtypes, the patients were divided into 3 subgroups: classic Hodgkin lymphoma (cHL), B-cell non-Hodgkin lymphoma (B-NHL), and T-cell non-Hodgkin lymphoma (T-NHL). The clinica...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Making long-term plans was not always part of Tanis Milicevic's daily routine. Milicevic was diagnosed with non-Hodgkin lymphoma more than a decade ago. But the past year has been markedly different for the Ponte Vedra Beach, Florida, resident. June 14 was her one-year anniversary as Florida's first successful chimeric antigen receptor therapy (CAR-T cell therapy) [...]
Source: Mayo Clinic Florida News - Category: Hospital Management Source Type: news
More News: Cancer | Cancer & Oncology | Legislation | Lymphoma | Medical Law | Non-Hodgkin's Lymphoma | Toxicology